Tae-Hwan Kim
0000-0002-3542-2276
한양대학교 류마티스병웜
7 papers found
Refreshing results…
Brodalumab, an anti–interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study
Response to: ‘Correspondence on ‘Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial’’ by Zhao and Huang
Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial
Negative Regulation of Osteoclast Commitment by Intracellular Protein Phosphatase Magnesium‐Dependent 1A
Malignancy risk in Korean male patients with ankylosing spondylitis
Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values
Missing publications? Search for publications with a matching author name.